secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001628280-24-023189
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncology Institute Q1 revenue up 24% to $95M; net loss narrows to $19.9M
------------------------------------------------------------------------

- Revenue of $95M (+24.2% YoY); net loss $19.9M vs $30.0M loss in prior year.
- Gross profit $12M (-15.1% YoY); gross margin 12.6% vs 18.5% a year ago.
- Adjusted EBITDA loss of $10.9M vs $7.4M loss in prior year quarter.
- Signed 7 new value-based contracts; reaffirmed full-year 2024 guidance.
- Ended Q1 with 73 clinics, 126 providers; scripts dispensed up 70% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000162828024023189/0001628280-24-023189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000162828024023189/toi-20240514.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-023189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer